Wednesday, 22 June 2016 05:18

Quality Metrics for Oncology in a Value-Based Reimbursement World

Written by Kim Charland, BA, RHIT, CCS, and Robin Zweifel, BS, MT (ASCP)

  Healthcare is rapidly transitioning from a fee-for-service (FFS) to a value-based reimbursement world. This transition accelerated when, in January 2015, HHS announced a new set of goals and a timeline for tying Medicare payments to quality or value through alternative payment models.

HHS goals included linking 30% (up from 20%) of traditional Medicare payments by the end of 2016 through accountable care organizations and bundled payments, and 50% by the end of 2018. HHS also set a goal of linking 85% of all traditional Medicare payments to quality or value by 2016, and 90% by 2018 through programs such as Hospital Value-Based Purchasing2 and the Hospital Readmission Reduction Program.

To read this article in its entirely, please click here.

Evidence-Based Oncology (EBO) is a forum for the dissemination of clinical, pharmacoeconomic, and regulatory information to payers, healthcare policy experts, and providers associated with cancer care. EBO’s mission is to publish research and commentaries relevant to clinical decision makers and policy makers as they work to promote the efficient delivery of high-quality cancer care.